{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:08:57Z","timestamp":1793668137561,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-063356"],"award-info":[{"award-number":["AI-063356"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-103960"],"award-info":[{"award-number":["AI-103960"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HD-044864"],"award-info":[{"award-number":["HD-044864"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HD-082273"],"award-info":[{"award-number":["HD-082273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HD-038416"],"award-info":[{"award-number":["HD-038416"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"City of Hope","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.vaccine.2015.06.019","type":"journal-article","created":{"date-parts":[[2015,6,14]],"date-time":"2015-06-14T13:42:52Z","timestamp":1434289372000},"page":"4013-4018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Comparison of monovalent glycoprotein B with bivalent gB\/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality"],"prefix":"10.1016","volume":"33","author":[{"given":"Elizabeth C.","family":"Swanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelmary","family":"Hernandez-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fern\u00e1ndez-Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Schmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Zabeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wussow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don J.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Schleiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.06.019_bib0255","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0260","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/187152611797636721","article-title":"Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis","volume":"11","author":"Schleiss","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0265","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0270","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/421999","article-title":"Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee","volume":"39","author":"Arvin","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2015.06.019_bib0275","doi-asserted-by":"crossref","first-page":"B197","DOI":"10.1016\/j.vaccine.2012.10.074","article-title":"Desirability and feasibility of a vaccine against cytomegalovirus","volume":"31","author":"Griffiths","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0280","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","article-title":"Priorities for CMV vaccine development","volume":"32","author":"Krause","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0285","doi-asserted-by":"crossref","first-page":"501801","DOI":"10.1155\/2013\/501801","article-title":"Cytomegalovirus in the neonate: immune correlates of infection and protection","volume":"2013","author":"Schleiss","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0290","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1586\/erv.10.125","article-title":"Update on the current status of cytomegalovirus vaccines","volume":"9","author":"Sung","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0295","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0300","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0305","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0310","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0315","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/fvl.13.106","article-title":"Developing a vaccine against congenital cytomegalovirus (CMV) infection: what have we learned from animal models? Where should we go next","volume":"8","author":"Schleiss","year":"2013","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0320","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-62703-788-4_15","article-title":"What we have learned from animal models of HCMV","volume":"1119","author":"Dogra","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0325","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1016\/j.vaccine.2013.04.078","article-title":"Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta","volume":"31","author":"Hashimoto","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0330","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1016\/j.vaccine.2009.04.036","article-title":"A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine\/challenge model of congenital cytomegalovirus infection","volume":"27","author":"Crumpler","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0335","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/138.2.197","article-title":"Cytomegalovirus infection in guinea pigs. II. Transplacental and horizontal transmission","volume":"138","author":"Choi","year":"1978","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0340","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/vim.2000.13.155","article-title":"Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83","volume":"13","author":"Schleiss","year":"2000","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0345","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1743-422X-8-89","article-title":"Intravaginal cytomegalovirus (CMV) challenge elicits maternal viremia and results in congenital transmission in a guinea pig model","volume":"8","author":"Olejniczak","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0350","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/j.1460-2075.1986.tb04606.x","article-title":"Identification of the human cytomegalovirus glycoprotein-b gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus","volume":"5","author":"Cranage","year":"1986","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0355","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/viro.1994.1294","article-title":"Identification of an abundant disulfide-linked complex of glycoproteins in the envelope of guinea pig cytomegalovirus","volume":"201","author":"Britt","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/viro.1994.1333","article-title":"Cloning and characterization of the guinea pig cytomegalovirus glycoprotein B gene","volume":"202","author":"Schleiss","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0365","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/JVI.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0370","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2014.05.011","article-title":"Development of a novel, guinea pig-specific IFN-gamma ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine","volume":"32","author":"Gillis","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0375","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/511982","article-title":"Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection","volume":"195","author":"Schleiss","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0380","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1086\/379839","article-title":"Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection","volume":"188","author":"Schleiss","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0385","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/382751","article-title":"Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine","volume":"189","author":"Schleiss","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0390","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1128\/JVI.01708-06","article-title":"Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques","volume":"81","author":"Yue","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0395","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00430-008-0074-5","article-title":"Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques","volume":"197","author":"Yue","year":"2008","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0400","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/JVI.79.1.159-175.2005","article-title":"Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge","volume":"79","author":"Morello","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0405","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/infdis\/172.4.944","article-title":"Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs","volume":"172","author":"Bratcher","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0410","doi-asserted-by":"crossref","first-page":"906948","DOI":"10.1155\/2013\/906948","article-title":"An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model","volume":"2013","author":"Leviton","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0415","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/v6020727","article-title":"Identification by mass spectrometry and immune response analysis of guinea pig cytomegalovirus (GPCMV) pentameric complex proteins GP129, 131 and 133","volume":"6","author":"Gnanandarajah","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0420","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2009.05.034","article-title":"Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130","volume":"391","author":"Yamada","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0425","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virol.2013.03.008","article-title":"Characterization of the guinea pig CMV gH\/gL\/GP129\/GP131\/GP133 complex in infection and spread","volume":"441","author":"Auerbach","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0430","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.vaccine.2013.07.010","article-title":"Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model","volume":"32","author":"Schleiss","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0435","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.vaccine.2006.09.067","article-title":"Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0440","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2003-10-3469","article-title":"Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0445","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1128\/JVI.78.8.3965-3976.2004","article-title":"Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus","volume":"78","author":"Wang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0450","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ilar.47.1.65","article-title":"Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns","volume":"47","author":"Schleiss","year":"2006","journal-title":"ILAR J"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0455","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0460","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1128\/JVI.00883-10","article-title":"Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques","volume":"85","author":"Abel","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0465","doi-asserted-by":"crossref","first-page":"11439","DOI":"10.1073\/pnas.1534570100","article-title":"Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells","volume":"100","author":"Browne","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0470","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1128\/JVI.78.20.10995-11006.2004","article-title":"Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response","volume":"78","author":"Abate","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0475","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.4161\/hv.21225","article-title":"Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus","volume":"8","author":"Hartikka","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0480","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1172\/JCI67420","article-title":"Cytomegalovirus pp65 limits dissemination but is dispensable for persistence","volume":"124","author":"Malouli","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0485","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0490","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1128\/JVI.01669-12","article-title":"A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques","volume":"87","author":"Wussow","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0495","doi-asserted-by":"crossref","first-page":"e1004524","DOI":"10.1371\/journal.ppat.1004524","article-title":"Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex","volume":"10","author":"Wussow","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2015.06.019_bib0500","doi-asserted-by":"crossref","first-page":"17965","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies","volume":"111","author":"Kabanova","year":"2014","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15007963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15007963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:53:14Z","timestamp":1599133994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15007963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":50,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0264410X15007963"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of monovalent glycoprotein B with bivalent gB\/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}